Skip to main content
Top
Published in: Endocrine 2/2012

01-04-2012 | Original Article

Clinical and radiological findings in macroprolactinemia

Authors: Serhat Isik, Dilek Berker, Yasemin Ates Tutuncu, Ufuk Ozuguz, Ferhat Gokay, Gonul Erden, Hatice Nursun Ozcan, Ferit Kerim Kucukler, Yusuf Aydin, Serdar Guler

Published in: Endocrine | Issue 2/2012

Login to get access

Abstract

Hyperprolactinemia is the most common abnormality of the hypothalamic–pituitary axis. The aim of this study was to investigate the clinical and radiological features of patients with macroprolactinemia. The study population consisted of patients with elevated serum prolactin (PRL) concentrations who presented to our Endocrinology outpatient clinic. Detection of macroprolactin (macroPRL) was performed using the polyethylene glycol precipitation method. Patients in which macroPRL made up more than 60% of total PRL levels were stratified into the macroPRL group, while the remaining patients were placed in the monomeric prolactin (monoPRL) group. A total of 337 patients were enrolled with a mean age of 33.8 ± 10.8 (16–66) years and a male/female ratio of 29/308. Eighty-eight of the patients (26.1%) had an elevated macroPRL level. The mean age in the monoPRL group was higher than in the macroPRL group (35.0 ± 10.1 vs. 30.7 ± 9.8, P = 0.016). The mean PRL levels (ng/ml) in the macroPRL and monoPRL groups were similar (168.0 ± 347.0 vs. 238.8 ± 584.9, P = 0.239). Frequency of amenorrhea, infertility, irregular menses, gynecomastia, and erectile dysfunction were also similar in both groups. More patients in the macroPRL group were asymptomatic compared to the monoPRL group (30.2 vs. 12.0%, P = 0.006). Compared to the macroPRL group, the monoPRL group had a higher frequency of galactorrhea (39.2 vs. 57.1%, P = 0.04) and abnormal magnetic resonance imaging findings (65.3 vs. 81.1%, P = 0.02). Elevated macroPRL levels should be considered a pathological biochemical variant of hyperprolactinemia that may present with any of the conventional symptoms and radiological findings generally associated with elevated PRL levels.
Literature
1.
go back to reference D.C Aron, J.W Findling, J.B Tyrrell, Hypothalamus and pituitary gland, in Basic and Clinical Endocrinology, 7th edn. by F.S. Greenspan, D.G Gardner (Lange Medical Books-McGraw Hill, New York 2004), pp. 106–175 D.C Aron, J.W Findling, J.B Tyrrell, Hypothalamus and pituitary gland, in Basic and Clinical Endocrinology, 7th edn. by F.S. Greenspan, D.G Gardner (Lange Medical Books-McGraw Hill, New York 2004), pp. 106–175
2.
go back to reference O.M. Hauache, A.J. Rocha, A.C. Maia Jr., R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. (Oxf) 57, 327–331 (2002)CrossRef O.M. Hauache, A.J. Rocha, A.C. Maia Jr., R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. (Oxf) 57, 327–331 (2002)CrossRef
3.
go back to reference H. Leslie, C.H. Courtney, P.M. Bell et al., Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J. Clin. Endocrinol. Metab. 86, 2743–2746 (2001)PubMedCrossRef H. Leslie, C.H. Courtney, P.M. Bell et al., Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J. Clin. Endocrinol. Metab. 86, 2743–2746 (2001)PubMedCrossRef
4.
go back to reference J.G. Vieira, T.T. Tachibana, L.H. Obara, R.M. Maciel, Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin. Chem. 44, 1758–1759 (1998)PubMed J.G. Vieira, T.T. Tachibana, L.H. Obara, R.M. Maciel, Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin. Chem. 44, 1758–1759 (1998)PubMed
5.
go back to reference M.R. Sánchez-Eixerés, M. Mauri, R. Alfayate et al., Prevalence of macroprolactin detected by Elecsys 2010. Horm. Res. 56, 87–92 (2001)PubMedCrossRef M.R. Sánchez-Eixerés, M. Mauri, R. Alfayate et al., Prevalence of macroprolactin detected by Elecsys 2010. Horm. Res. 56, 87–92 (2001)PubMedCrossRef
6.
go back to reference T.P. Smith, A.M. Suliman, M.N. Fahie-Wilson, T.J. McKenna, Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J. Clin. Endocrinol. Metab. 87, 5410–5415 (2002)PubMedCrossRef T.P. Smith, A.M. Suliman, M.N. Fahie-Wilson, T.J. McKenna, Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J. Clin. Endocrinol. Metab. 87, 5410–5415 (2002)PubMedCrossRef
7.
go back to reference S. Vallette-Kasic, I. Morange-Ramos, A. Selim et al., Macroprolactinemia revisited: A study on 106 patients. J. Clin. Endocrinol. Metab. 87, 581–588 (2002)PubMedCrossRef S. Vallette-Kasic, I. Morange-Ramos, A. Selim et al., Macroprolactinemia revisited: A study on 106 patients. J. Clin. Endocrinol. Metab. 87, 581–588 (2002)PubMedCrossRef
8.
go back to reference B. Cavaco, V. Leite, M.A. Santos, E. Arranhado, L.G. Sobrinho, Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J. Clin. Endocrinol. Metab. 80, 2342–2346 (1995)PubMedCrossRef B. Cavaco, V. Leite, M.A. Santos, E. Arranhado, L.G. Sobrinho, Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J. Clin. Endocrinol. Metab. 80, 2342–2346 (1995)PubMedCrossRef
9.
go back to reference V. Leite, H. Cosby, L.G. Sobrinho, M.A. Fresnoza, M.A. Santos, H.G. Friesen, Characterization of big, big prolactin in patients with hyperprolactinemia. Clin. Endocrinol. (Oxf) 37, 365–372 (1992)CrossRef V. Leite, H. Cosby, L.G. Sobrinho, M.A. Fresnoza, M.A. Santos, H.G. Friesen, Characterization of big, big prolactin in patients with hyperprolactinemia. Clin. Endocrinol. (Oxf) 37, 365–372 (1992)CrossRef
10.
go back to reference T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. N. Am. 37(1), 67–99 (2008)CrossRef T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. N. Am. 37(1), 67–99 (2008)CrossRef
11.
go back to reference A.O. Olukoga, J.W. Kane, Macroprolactinaemia: Validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. (Oxf) 51, 119–126 (1999)CrossRef A.O. Olukoga, J.W. Kane, Macroprolactinaemia: Validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. (Oxf) 51, 119–126 (1999)CrossRef
12.
go back to reference A.M. Suliman, T.P. Smith, J. Gibney, T.J. McKenna, Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: Application of a new strict laboratory definition of macroprolactinemia. Clin. Chem. 49, 1504–1509 (2003)PubMedCrossRef A.M. Suliman, T.P. Smith, J. Gibney, T.J. McKenna, Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: Application of a new strict laboratory definition of macroprolactinemia. Clin. Chem. 49, 1504–1509 (2003)PubMedCrossRef
13.
go back to reference K. Ichihara, K. Miyai, Detection of asymptomatic prolactinoma by a mass screening program. Rinsho Byori 38, 667–674 (1990)PubMed K. Ichihara, K. Miyai, Detection of asymptomatic prolactinoma by a mass screening program. Rinsho Byori 38, 667–674 (1990)PubMed
14.
go back to reference T. Bjøro, L. Mørkrid, R. Wergeland et al., Frequency of hyperprolactinaemia due to large molecular weight prolactin (150–170 kD PRL) Scand. J. Clin. Lab. Invest. 55, 139–147 (1995)CrossRef T. Bjøro, L. Mørkrid, R. Wergeland et al., Frequency of hyperprolactinaemia due to large molecular weight prolactin (150–170 kD PRL) Scand. J. Clin. Lab. Invest. 55, 139–147 (1995)CrossRef
15.
go back to reference M.N. Fahie-Wilson, S.G. Soule, Macroprolactinaemia: Contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann. Clin. Biochem. 34, 252–258 (1997)PubMed M.N. Fahie-Wilson, S.G. Soule, Macroprolactinaemia: Contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann. Clin. Biochem. 34, 252–258 (1997)PubMed
16.
go back to reference Y.N. Sinha, Structural variants of prolactin: Occurrence and physiological significance. Endocr. Rev. 16, 354–369 (1995)PubMed Y.N. Sinha, Structural variants of prolactin: Occurrence and physiological significance. Endocr. Rev. 16, 354–369 (1995)PubMed
17.
go back to reference C.R. Smith, M.R. Norman, Prolactin and growth hormone: molecular heterogeneity and measurement in serum. Ann. Clin. Biochem. 27, 542–550 (1990)PubMed C.R. Smith, M.R. Norman, Prolactin and growth hormone: molecular heterogeneity and measurement in serum. Ann. Clin. Biochem. 27, 542–550 (1990)PubMed
18.
go back to reference S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, Endocrine Society Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)PubMedCrossRef S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, Endocrine Society Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)PubMedCrossRef
19.
go back to reference J. Gibney, T.P. Smith, T.J. McKenna, The impact on clinical practice of routine screening for macroprolactin. J. Clin. Endocrinol. Metab. 90, 3927–3932 (2005)PubMedCrossRef J. Gibney, T.P. Smith, T.J. McKenna, The impact on clinical practice of routine screening for macroprolactin. J. Clin. Endocrinol. Metab. 90, 3927–3932 (2005)PubMedCrossRef
20.
go back to reference F.F. Casanueva, M.E. Molitch, J.A. Schlechte et al., Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf) 65(2), 265–273 (2006)CrossRef F.F. Casanueva, M.E. Molitch, J.A. Schlechte et al., Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf) 65(2), 265–273 (2006)CrossRef
21.
go back to reference I.R. Wallace, N. Satti, C.H. Courtney, H. Leslie, P.M. Bell, S.J. Hunter, D.R. McCance, B. Sheridan, A.B. Atkinson, Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J. Clin. Endocrinol. Metab. 95(7), 3268–3271 (2010)PubMedCrossRef I.R. Wallace, N. Satti, C.H. Courtney, H. Leslie, P.M. Bell, S.J. Hunter, D.R. McCance, B. Sheridan, A.B. Atkinson, Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J. Clin. Endocrinol. Metab. 95(7), 3268–3271 (2010)PubMedCrossRef
22.
go back to reference T. Rand, E. Kink, M. Sator et al., MRI of microadenomas in patients with hyperprolactinemia. Neuroradiology 38, 744–746 (1996)PubMedCrossRef T. Rand, E. Kink, M. Sator et al., MRI of microadenomas in patients with hyperprolactinemia. Neuroradiology 38, 744–746 (1996)PubMedCrossRef
23.
go back to reference A. Bayrak, P. Saadat, E. Mor, L. Chong, R.J. Paulson, R.Z. Sokol, Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil. Steril. 84, 181–185 (2005)PubMedCrossRef A. Bayrak, P. Saadat, E. Mor, L. Chong, R.J. Paulson, R.Z. Sokol, Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil. Steril. 84, 181–185 (2005)PubMedCrossRef
24.
go back to reference G. Tamer, A. Telci, M. Mert, et al., Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine. (2011) G. Tamer, A. Telci, M. Mert, et al., Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine. (2011)
25.
go back to reference P.E. Garnier, M.L. Aubert, S.L. Kaplan, M.M. Grumbach, Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of “big” prolactin in a radioreceptor assay and evidence for its secretion. J. Clin. Endocrinol. Metab. 47, 1273–1281 (1978)PubMedCrossRef P.E. Garnier, M.L. Aubert, S.L. Kaplan, M.M. Grumbach, Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of “big” prolactin in a radioreceptor assay and evidence for its secretion. J. Clin. Endocrinol. Metab. 47, 1273–1281 (1978)PubMedCrossRef
26.
go back to reference A.D. Rogol, R.C. Eastman, T. Manolio, S.W. Rosen, Unusual heterogeneity of circulating prolactin in an acromegalic. J. Endocrinol. Invest. 4, 221–227 (1981)PubMed A.D. Rogol, R.C. Eastman, T. Manolio, S.W. Rosen, Unusual heterogeneity of circulating prolactin in an acromegalic. J. Endocrinol. Invest. 4, 221–227 (1981)PubMed
27.
go back to reference F. Larrea, C. Villanueva, M. Carmen Cravioto, A. Escorza, O. del Real, Further evidence that big–big prolactin is preferentially secreted in women with hyperprolactinemia and normal ovarian function. Fertil. Steril. 44, 25–30 (1985)PubMed F. Larrea, C. Villanueva, M. Carmen Cravioto, A. Escorza, O. del Real, Further evidence that big–big prolactin is preferentially secreted in women with hyperprolactinemia and normal ovarian function. Fertil. Steril. 44, 25–30 (1985)PubMed
28.
go back to reference N. Hattori, K. Ikekubo, T. Ishihara, K. Moridera, M. Hino, H. Kurahachi, Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur. J. Endocrinol. 130, 438–445 (1994)PubMedCrossRef N. Hattori, K. Ikekubo, T. Ishihara, K. Moridera, M. Hino, H. Kurahachi, Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur. J. Endocrinol. 130, 438–445 (1994)PubMedCrossRef
29.
go back to reference D.L. Kleinberg, G.L. Noel, A.G. Frantz, Galactorrhea: A study of 235 cases including 48 with pituitary tumors. N. Engl. J. Med. 296, 589–600 (1977)PubMedCrossRef D.L. Kleinberg, G.L. Noel, A.G. Frantz, Galactorrhea: A study of 235 cases including 48 with pituitary tumors. N. Engl. J. Med. 296, 589–600 (1977)PubMedCrossRef
Metadata
Title
Clinical and radiological findings in macroprolactinemia
Authors
Serhat Isik
Dilek Berker
Yasemin Ates Tutuncu
Ufuk Ozuguz
Ferhat Gokay
Gonul Erden
Hatice Nursun Ozcan
Ferit Kerim Kucukler
Yusuf Aydin
Serdar Guler
Publication date
01-04-2012
Publisher
Springer US
Published in
Endocrine / Issue 2/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9576-9

Other articles of this Issue 2/2012

Endocrine 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.